Income Statement for ZVSA

	ZyVersa Therapeutics, Inc. (ZVSA)
	Q4-CY2025	Q3-CY2025	Q2-CY2025	Q1-CY2025	Q4-CY2024	Q3-CY2024	Q2-CY2024	Q1-CY2024	Q4-CY2023	Q3-CY2023	Q2-CY2023	Q1-CY2023	Q4-CY2022	Q3-CY2022	Q2-CY2022	Q1-CY2022	Q4-CY2021	Q3-CY2021	Q2-CY2021	Q1-CY2021	Q4-CY2020	Q3-CY2020	Q2-CY2020	Q1-CY2020	Q4-CY2019	Q3-CY2019	Q2-CY2019	Q1-CY2019	Q4-CY2018	Q3-CY2018	Q2-CY2018	Q1-CY2018	Q4-CY2017	Q3-CY2017	Q2-CY2017	Q1-CY2017	Q4-CY2016	Q3-CY2016	Q2-CY2016	Q1-CY2016	Q4-CY2015	Q3-CY2015	Q2-CY2015	Q1-CY2015	Q4-CY2014	Q3-CY2014	Q2-CY2014	Q1-CY2014	Q4-CY2013
Balance Sheet Date		2025-Sep-30	2025-Jun-30	2025-Mar-31	2024-Dec-31	2024-Sep-30	2024-Jun-30	2024-Mar-31	2023-Dec-31
Fiscal Period		Q3-FY2025	Q2-FY2025	Q1-FY2025	Q4-FY2024	Q3-FY2024	Q2-FY2024	Q1-FY2024	Q4-FY2023
Total Revenue		(131,350$)	(130,036$)	(119,559$)	(138,062$)	(131,635$)	(58$)	(101$)	(98$)	(210$)	(314$)	1,078$
QoQ%		(1.01%)	(8.76%)	13.40%	(4.88%)	(226,856.90%)	42.57%	(3.06%)	53.33%	33.12%	(129.13%)
YoY%		.22%	(224,100.00%)	(118,275.25%)	(140,779.59%)	(62,583.33%)	81.53%	(109.37%)
Cost Of Revenue		0$	0$	0$	0$	0$	0$	0$	0$	0$	0$	0$
Gross Profit		(131,350$)	(130,036$)	(119,559$)	(138,062$)	(131,635$)	(58$)	(101$)	(98$)	(210$)	(314$)	1,078$
Gross Margin		100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
Operating Expenses		20,752,130$	2,044,132$	2,144,571$	1,286,599$	2,269,621$	2,753,978$	2,826,636$	13,934,470$	2,902,678$	86,325,005$	4,592,079$
Operating Income		(20,752,130$)	(2,044,132$)	(2,144,571$)	(1,286,599$)	(2,269,621$)	(2,753,978$)	(2,826,636$)	(13,934,470$)	(2,902,678$)	(86,325,005$)	(4,592,079$)
Operating Margin		15,799.11%	1,571.97%	1,793.73%	931.90%	1,724.18%	4,748,237.93%	2,798,649.51%	14,218,846.94%	1,382,227.62%	27,492,039.81%	(425,981.35%)
Interest Income
Interest Expenses		131,350$	130,036$	119,559$	138,062$	131,635$	58$	101$	98$	210$	314$	0$
Income Before Tax		(20,657,218$)	(2,211,317$)	(2,256,930$)	(1,424,661$)	(2,401,256$)	(2,754,036$)	(2,826,737$)	(13,934,568$)	(2,902,888$)	(86,325,319$)	(4,591,001$)
Tax Expenses		(851,659$)			(2,962$)	0$	9,707$		(596,068$)	(485$)	(7,812,226$)	(1,047,051$)
Net Income		(19,805,559$)	(2,211,317$)	(2,256,930$)	(1,421,699$)	(2,401,256$)	(2,763,743$)	(2,826,737$)	(13,338,500$)	(2,902,403$)	(78,513,093$)	(3,543,950$)
Profit Margin		15,078.46%	1,700.54%	1,887.71%	1,029.75%	1,824.18%	4,765,074.14%	2,798,749.51%	13,610,714.29%	1,382,096.67%	25,004,169.75%	(328,752.32%)
TTM		4,950.90%	1,596.64%	2,271.59%	3,488.32%	16,172.50%	4,674,814.35%	13,496,643.57%	(21,556,567.11%)
Earnings to Minority										32,373$	7,915,836$
Earnings to Common Shareholders		(19,805,559$)	(2,211,317$)	(2,256,930$)	(1,421,699$)	(2,401,256$)	(2,763,743$)	(2,826,737$)	(13,338,500$)	(2,934,776$)	(86,428,929$)	(3,543,950$)
QoQ%		(795.65%)	2.02%	(58.75%)	40.79%	13.12%	2.23%	78.81%	(354.50%)	96.60%	(2,338.77%)
YoY%		(724.80%)	19.99%	20.16%	89.34%	18.18%	96.80%	20.24%
Earnings Per Share, Basic		(2.56$)	(0.46$)	(0.73$)	(0.71$)	(2.43$)	(3.31$)	(4.53$)	(61.85$)	(30.18$)	(1,694.12$)	(135.88$)
Earnings Per Share, Diluted		(2.56$)	(0.46$)	(0.73$)	(0.71$)	(2.43$)	(3.31$)	(4.53$)	(61.85$)	(30.18$)	(1,694.12$)	(135.88$)
Unlevered FCF Per Share, Basic		(0.18$)	(0.32$)	(0.57$)	(0.63$)	(0.62$)	(2.29$)	(6.06$)	(12.93$)	(9.63$)	(7.99$)	(175.97$)
Unlevered FCF Per Share, Diluted		(0.18$)	(0.32$)	(0.57$)	(0.63$)	(0.62$)	(2.29$)	(6.06$)	(12.93$)	(9.63$)	(7.99$)	(175.97$)
Average Shares, Basic		7,740,678	4,814,115	3,106,928	1,993,239	988,378	834,915	623,600	215,650	97,252	51,017	26,081
Average Shares, Diluted		7,740,678	4,814,115	3,106,928	1,993,239	988,378	834,915	623,600	215,650	97,252	51,017	26,081
EBIT		(20,525,868$)	(2,081,281$)	(2,137,371$)	(1,286,599$)	(2,269,621$)	(2,753,978$)	(2,826,636$)	(13,934,470$)	(2,902,678$)	(86,325,005$)	(4,591,001$)
EBITDA		(20,525,868$)	(2,081,281$)	(2,137,371$)	(1,286,599$)	(2,269,621$)	(2,753,978$)	(2,826,636$)	(13,934,470$)	(2,902,678$)	(86,325,005$)	(4,591,001$)